Regeneron CEO Leonard Schleifer said on Sunday that the ability of the company’s antibody cocktail that was administered to President Trump to treat a coronavirus case was simply a “clinical case” or a singular event, despite the president calling the experimental drug a “cure”.
“It’s proof of what’s happening, but it’s the weakest proof you can get,”
TRUMP PUSHES FDA TO ACCELERATE REVIEW OF REGENERON AND ELI LILLY COVID-19 TREATMENTS: REPORT
While Schleifer said there are some “very interesting aspects” of the president’s case, such as his age, risk factors and immune system, he argued that real evidence of the drug’s effectiveness will come from the larger randomized clinical trials. that are in progress and displayed. as a “gold standard”.
“We have some preliminary evidence that we have spoken with the FDA, and we are going for an emergency use authorization, because we think it is appropriate right now,” added Schleifer. “But yes, the president’s case is a case report, perhaps the most analyzed case report ever, but it’s only low on the scale of evidence that we really need.”
His comments come just days after the president took to Twitter urging regulators to approve the pharmaceutical company’s emergency use authorization request for therapeutic treatment.
“I walked in, I didn’t feel that hot and in a very short period of time they gave me Regeneron, it’s called Regeneron, and other things as well but I think that was the key. It was amazing and I immediately felt good. I felt good three days ago like now, “Trump said. “I have all the emergency use permissions set and we need to get it signed now. And you will improve, you will improve very quickly.”
The president also reportedly contacted the head of the Food and Drug Administration to push for approval of the emergency use authorization of antibody treatment as the window of opportunity for an effective vaccine closes before election day.
CLICK HERE TO READ MORE FOX BUSINESS STORIES
The U.S. government struck a $ 450 million deal with Regeneron in July to purchase approximately 300,000 doses of the antibody cocktail treatment, which the president said he would make free.
However, Schleifer noted that it will take much longer than Regeneron’s treatment to end the pandemic.
“We need the whole industry and I’m so proud the industry has grown,” said Schiefler. “We have companies like Lilly, big companies. We are partners with Roche, one of the best companies in this field. Amgen is involved. AstraZeneca is involved. Black-Scholes is involved. We all have to step up if we want to ‘) we will provide enough. “.
|REGN||REGENERON PHARMACEUTICALS INC.||602.07||+2.19||+ 0.37%|
There are more than 7.7 million confirmed cases of the coronavirus in the United States and more than 214,000 related deaths, according to the latest update from Johns Hopkins University.
GET BUSINESS FOX ON THE GO BY CLICKING HERE